The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Treatment options for idiopathic multicentric Castleman disease (iMCD) are currently limited, especially for patients who do not respond or are resistant to interleukin‐6 inhibitors. For the first time, we innovatively designed a protocol using rituximab–bortezomib–dexamethasone (RVD) as first‐line consolidation therapy in patients newly diagnosed with iMCD. Furthermore, we adopted a no‐maintenance...
There have been reports of haematological cancer patients achieving spontaneous remission after being infected with the influenza A or SARS‐COV‐2 virus. Here, we present the first case of long‐term complete remission (CR) induced by influenza A (IAV, H1N1 subtype) in a refractory AML patient and have functionally validated this finding in two different animal disease models. We observed a significant...